Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2007

View Archived Issues

Crucell's West Nile vaccine meets phase I study endpoints

Nasalfent begins phase III program in breakthrough cancer pain

New phase I/II trial under way for TNFerade in head and neck cancer

IND acceptance for SPC/ENZ-2968 triggers milestone payment

Aranesp increases risk of death in cancer patients not receiving treatment

Novel inhibitor of protein-protein interactions in the Wnt pathway suppresses tumor growth in vivo

Oral entry inhibitor SP-10 shows antiviral activity in HCV

VRX-480773: a novel NNRTI with activity against efavirenz-resistant HIV

LAB International closes PharmaForm acquisition

Recent patents describe new agents for musculoskeletal and connective tissue disorders

Recent patents report novel therapeutic agents for HIV infection

New agents for schizophrenia and depression disclosed in recent patents

Targeting orexin receptors may be useful to treat sleep disorders

Yaz approved to treat acne in women

Promising phase II findings for INGN-225 in small cell lung cancer

GSK files prepandemic influenza vaccine in E.U.

Sunesis to advance phase II SCLC study of SNS-595 into second stage

Phase II trial explores topical AVR-118 as wound healing agent

RPI-78M begins phase IIb study in adrenomyeloneuropathy

Intravenous administration approved for Vidaza

Phase II enrollment open for glufosfamide in platinum-resistant ovarian cancer

Preliminary findings from phase IIb asthma study of IPL-512,602

DiabeCell cleared for Russian study in type 1 diabetes

Lexicon changes name, refocuses operations on drug discovery and development

Mirena approved in Japan

Pariet approved in Japan for H. pylori eradication

Relenza approved in Japan for influenza prophylaxis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...